-
EP1849470
European procedure
Extract from the Register of European Patents
EP About this file: EP1849470
| EP1849470 - ANTICANCER DRUG CONTAINING ALPHA, ALPHA, ALPHA-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR [Right-click to bookmark this link] | |||
| Former [2007/44] | ANTICANCER DRUG CONTAINING ALPHA, ALPHA, ALPHATRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR | ||
| [2017/01] | Status | Patent maintained as amended Status updated on 16.02.2024 Database last updated on 19.10.2024 | |
| Former | The patent has been granted Status updated on 19.05.2017 | ||
| Former | Grant of patent is intended Status updated on 02.01.2017 | Most recent event Tooltip | 16.02.2024 | Patent maintained (B2 publication) | published on 20.03.2024 [2024/12] | Applicant(s) | For all designated states Taiho Pharmaceutical Co., Ltd. 1-27 Kandanishiki-cho Chiyoda-ku Tokyo 101-8444 / JP | [2017/25] |
| Former [2007/44] | For all designated states TAIHO PHARMACEUTICAL COMPANY LIMITED 27 Kanda Nishiki-cho 1-chome Chiyoda-ku Tokyo 101-8444 / JP | Inventor(s) | 01 /
EMURA, Tomohiro c/o Taiho Pharmaceutical Co., Ltd., 1-27, Misugidai Hanno-shi, Saitama, 357-8527 / JP | 02 /
MITA, Akira c/o Taiho Pharmaceutical Co., Ltd., 1-19, Kandanishiki-cho Chiyoda-ku, Tokyo, 101-0054 / JP | [2017/04] |
| Former [2007/44] | 01 /
EMURA, Tomohiro c/o Taiho Pharmaceutical Co., Ltd., 1-27, Misugida i, Hanno-shi, Saitama, 3578527 / JP | ||
| 02 /
MITA, Akira c/o Taiho Pharmaceutical Co., Ltd., 1-19, Kandanis hiki-cho, Chiyoda-ku, Tokyo, 1010054 / JP | Representative(s) | Hartz, Nikolai, et al Wächtershäuser & Hartz Patentanwaltspartnerschaft mbB Weinstrasse 8 80333 München / DE | [2017/25] |
| Former [2009/39] | Hartz, Nikolai, et al Wächtershäuser & Hartz Patentanwälte Weinstrasse 8 80333 München / DE | ||
| Former [2007/44] | Hartz, Nikolai, et al Wächtershäuser & Hartz, Patentanwälte, Weinstrasse 8 80333 München / DE | Application number, filing date | 06712292.9 | 25.01.2006 | [2007/44] | WO2006JP301097 | Priority number, date | US20050042059 | 26.01.2005 Original published format: US 42059 | JP20050165156 | 06.06.2005 Original published format: JP 2005165156 | [2007/44] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2006080327 | Date: | 03.08.2006 | Language: | JA | [2006/31] | Type: | A1 Application with search report | No.: | EP1849470 | Date: | 31.10.2007 | Language: | EN | [2007/44] | Type: | B1 Patent specification | No.: | EP1849470 | Date: | 21.06.2017 | Language: | EN | [2017/25] | Type: | B2 New European patent specification | No.: | EP1849470 | Date: | 20.03.2024 | Language: | EN | [2024/12] | Search report(s) | International search report - published on: | JP | 03.08.2006 | (Supplementary) European search report - dispatched on: | EP | 09.11.2010 | Classification | IPC: | A61K31/7072, A61K31/506, A61K31/513, A61K31/7068, A61P35/00 | [2017/02] | CPC: |
A61K31/506 (EP,KR);
A61K31/7068 (EP);
A61P35/00 (EP);
A61P43/00 (EP)
| C-Set: |
A61K31/506, A61K2300/00 (EP);
A61K31/7068, A61K2300/00 (EP) |
| Former IPC [2017/01] | A61K31/7072, A61K31/513, A61P35/00 | ||
| Former IPC [2010/49] | A61K31/7068, A61K31/506, A61P35/00, A61K31/513, A61K31/7072, A61K45/06 | ||
| Former IPC [2007/44] | A61K31/7068, A61K31/506, A61P35/00 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2017/25] |
| Former [2007/44] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | Extension states | AL | Not yet paid | BA | Not yet paid | HR | Not yet paid | MK | Not yet paid | YU | Not yet paid | Title | German: | ARZNEISTOFF GEGEN KREBS MIT ALPHA, ALPHA, ALPHA-TRIFLUORTHYMIDIN UND THYMIDIN-PHOSPHORYLASE-INHIBITOR | [2007/44] | English: | ANTICANCER DRUG CONTAINING ALPHA, ALPHA, ALPHA-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR | [2017/01] | French: | MÉDICAMENTS ANTICANCÉREUX CONTENANT DE LA ALPHA, ALPHA, ALPHA-TRIFLUOROTHYMIDINE ET UN INHIBITEUR DE LA THYMIDINE PHOSPHORYLASE | [2007/44] |
| Former [2007/44] | ANTICANCER DRUG CONTAINING ALPHA, ALPHA, ALPHATRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR | Entry into regional phase | 19.07.2007 | Translation filed | 19.07.2007 | National basic fee paid | 19.07.2007 | Search fee paid | 19.07.2007 | Designation fee(s) paid | 19.07.2007 | Examination fee paid | Examination procedure | 19.07.2007 | Examination requested [2007/44] | 17.03.2011 | Amendment by applicant (claims and/or description) | 27.10.2011 | Despatch of a communication from the examining division (Time limit: M06) | 15.03.2012 | Reply to a communication from the examining division | 03.12.2014 | Despatch of a communication from the examining division (Time limit: M06) | 12.06.2015 | Reply to a communication from the examining division | 03.01.2017 | Communication of intention to grant the patent | 09.05.2017 | Fee for grant paid | 09.05.2017 | Fee for publishing/printing paid | 09.05.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 27.10.2011 | Opposition(s) | Opponent(s) | 01
21.03.2018
ADMISSIBLE STADA Arzneimittel AG Stadastrasse 2-18 61118 Bad Vilbel / DE Opponent's representative Hamm&Wittkopp Patentanwälte PartmbB Jungfernstieg 38 20354 Hamburg / DE | 02
21.03.2018
ADMISSIBLE Generics (U.K.) Limited Building 4, Trident Place Mosquito Way Hatfield Herts AL 10 9UL / GB Opponent's representative Ter Meer Steinmeister & Partner, et al, et al Patentanwälte mbB Nymphenburger Straße 4 80335 München / DE | [2018/17] | 04.04.2018 | Invitation to proprietor to file observations on the notice of opposition | 14.08.2018 | Reply of patent proprietor to notice(s) of opposition | 07.06.2019 | Date of oral proceedings | 16.07.2019 | Despatch of interlocutory decision in opposition | 16.07.2019 | Despatch of minutes of oral proceedings | 19.07.2023 | Legal effect of interlocutory decision in opposition | 05.12.2023 | Despatch of communication that the patent will be maintained as amended | 09.02.2024 | Fee for printing new specification paid | Appeal following opposition | 25.09.2019 | Appeal received No. T2735/19 | 25.11.2019 | Statement of grounds filed | 19.07.2023 | Result of appeal procedure: appeal of the opponent was rejected | 06.11.2023 | Despatch of the decision of the Board of Appeal | 19.07.2023 | Date of oral proceedings | Fees paid | Renewal fee | 19.07.2007 | Renewal fee patent year 03 | 29.01.2009 | Renewal fee patent year 04 | 20.01.2010 | Renewal fee patent year 05 | 20.01.2011 | Renewal fee patent year 06 | 17.01.2012 | Renewal fee patent year 07 | 09.01.2013 | Renewal fee patent year 08 | 20.01.2014 | Renewal fee patent year 09 | 30.01.2015 | Renewal fee patent year 10 | 29.01.2016 | Renewal fee patent year 11 | 31.01.2017 | Renewal fee patent year 12 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | Opposition | EP0763529 | WO2006080327 |